Swedish nephrology company Calliditas Therapeutics (Nasdaq: CALT) has highlighted new analyses from the Phase III NefIgArd study.
The trial is evaluating Tarpeyo (budesonide) as an option for people with primary IgA nephropathy (IgAN), a progressive and chronic autoimmune condition which is also known as Berger’s disease.
Presented at the American Society of Nephrology (ASN) Kidney Week, the data show a smaller proportion of patients experiencing a 30% reduction in estimated glomerular filtration rate (eGFR), a key measure of kidney function.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze